Xylitol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Xylitol: From No Recorded Indication to Predicted Meningococcal Infection
One-Sentence Summary
Xylitol (DrugBank DB11195) currently has no approved indication or market authorization on record in India. The TxGNN model predicts a possible association with Meningococcal Infection, but this prediction is based solely on knowledge graph inference, with no supporting clinical trials or literature currently identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication on record |
| Predicted New Indication | Meningococcal Infection |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Xylitol is not available in this evidence pack. Xylitol has no recorded original indication or market authorization in India, so no pharmacological baseline exists from which to anchor a mechanistic comparison.
The TxGNN knowledge graph assigns a high prediction score (0.997) linking Xylitol to meningococcal infection, but this score reflects graph-based statistical association rather than a validated causal or mechanistic pathway. It is worth noting — as background context only — that xylitol has been studied for its nasopharyngeal anti-adhesion properties in the context of otitis media and sinusitis prevention, which could theoretically extend to reducing nasopharyngeal colonization by Neisseria meningitidis. However, no clinical trials or peer-reviewed literature in this evidence pack support this hypothesis, so it remains an untested, purely computational association.
Given the absence of MOA data, original indication data, and any corroborating trial or literature evidence, this prediction should be treated as exploratory only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Xylitol is not currently marketed in India, and no registrations are on record in this dataset. No authorization details are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN knowledge graph score (L5 evidence), with no clinical trials, literature, mechanism of action data, or market presence in India to substantiate a repurposing case for meningococcal infection.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Xylitol
- Preclinical or in-vitro evidence specifically addressing anti-adhesion/antimicrobial activity against Neisseria meningitidis
- At least one supporting clinical trial or peer-reviewed publication
- Regulatory safety data (warnings, contraindications, drug interactions) — currently unavailable (Blocking data gap per meta.data_gaps DG001)
- Confirmation of Indian market/regulatory pathway if development is to proceed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.